

Resource Summary Report

Generated by [RRID](#) on Aug 11, 2026

Human CXCL11/I-TAC Antibody

RRID:AB_2088019

Type: Antibody

Proper Citation

R and D Systems Cat# MAB672, RRID:AB_2088019

Antibody Information

URL: http://antibodyregistry.org/AB_2088019

Proper Citation: R and D Systems Cat# MAB672, RRID:AB_2088019

Target Antigen: CXCL11/I-TAC

Host Organism: Mouse

Clonality: monoclonal

Comments: Applications: Western Blot, Neutralization, ELISA Capture (Matched Antibody Pair)

Antibody Name: Human CXCL11/I-TAC Antibody

Description: This monoclonal targets CXCL11/I-TAC

Target Organism: Human

Clone ID: 87328

Antibody ID: AB_2088019

Vendor: R and D Systems

Catalog Number: MAB672

Alternative Catalog Numbers: MAB672-100, MAB672-SP, MAB672-500

Record Creation Time: 20250820T020847+0000

Record Last Update: 20250820T124847+0000

Ratings and Alerts

No rating or validation information has been found for Human CXCL11/I-TAC Antibody.

No alerts have been found for Human CXCL11/I-TAC Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang Z, et al. (2026) DPPA inhibits melanoma by targeting angiogenesis through activating autocrine IFN- γ -CXCL9/10/11-CXCR3 axis in vascular endothelial cells. iScience, 29(6), 116309.

Li HS, et al. (2025) RANKL/PD-1 dual blockade demonstrates survival benefit for patients with advanced lung adenocarcinoma harboring KRAS mutations. Cell reports. Medicine, 6(7), 102235.

Cutilli A, et al. (2025) Interferon-gamma induces epithelial reprogramming driving CXCL11-mediated T-cell migration. Journal of leukocyte biology, 117(2).

Wang W, et al. (2019) Type I Interferon Therapy Limits CNS Autoimmunity by Inhibiting CXCR3-Mediated Trafficking of Pathogenic Effector T Cells. Cell reports, 28(2), 486.